First Time Loading...
M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 27.84 CNY 2.5% Market Closed
Updated: May 4, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

5.1B
+1%
Assets
Growth Rates:
1 Year
+18%
3 Years
+44%
5 Years
+83%
7 Years
+101%
10 Years
+158%
1.5B
+9%
Liabilities
Growth Rates:
1 Year
+47%
3 Years
+74%
5 Years
+153%
7 Years
+120%
10 Years
+143%
3.6B
-2%
Equity
Growth Rates:
1 Year
+9%
3 Years
+34%
5 Years
+63%
7 Years
+93%
10 Years
+165%

Balance Sheet Decomposition
Mayinglong Pharmaceutical Group Co Ltd

5.1B
Assets
1.5B
Liabilities
5.1B
Assets
1.5B
Liabilities
Current Assets 4.2B
Cash & Short-Term Investments 3B
Receivables 648.8m
Other Current Assets 635.9m
Non-Current Assets 871.3m
Long-Term Investments 153.2m
PP&E 536.4m
Intangibles 114.1m
Other Non-Current Assets 67.5m
Current Liabilities 788.1m
Accounts Payable 174.6m
Accrued Liabilities 101.7m
Short-Term Debt 173.1m
Other Current Liabilities 338.7m
Non-Current Liabilities 732.2m
Long-Term Debt 516.3m
Other Non-Current Liabilities 216m

Balance Sheet
Mayinglong Pharmaceutical Group Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022
Assets
Cash & Cash Equivalents
795
681
691
548
924
1 090
1 774
2 043
2 410
2 340
Cash
8
7
7
8
7
10
1
1
2 407
2 310
Cash Equivalents
787
674
684
540
917
1 080
1 773
2 043
3
30
Short-Term Investments
40
52
29
21
208
81
94
36
106
813
Total Receivables
493
577
543
550
435
526
425
418
293
471
Accounts Receivables
185
193
192
182
128
102
84
102
123
247
Other Receivables
308
384
351
368
308
424
341
316
170
223
Inventory
184
236
215
213
200
229
281
268
314
336
Other Current Assets
72
97
272
465
324
341
68
346
238
266
Total Current Assets
1 585
1 643
1 750
1 797
2 091
2 267
2 643
3 111
3 361
4 226
PP&E Net
274
308
407
387
345
324
309
344
445
522
PP&E Gross
274
308
407
387
345
324
309
344
445
522
Accumulated Depreciation
167
175
191
215
234
263
283
312
355
422
Intangible Assets
22
23
27
32
33
38
43
62
67
80
Goodwill
18
24
23
22
19
15
6
25
25
25
Long-Term Investments
87
128
143
195
191
207
210
226
177
151
Other Long-Term Assets
42
60
59
64
74
77
74
98
52
53
Other Assets
18
24
23
22
19
15
6
25
25
25
Total Assets
2 028
N/A
2 186
+8%
2 410
+10%
2 497
+4%
2 754
+10%
2 927
+6%
3 285
+12%
3 867
+18%
4 127
+7%
5 058
+23%
Liabilities
Accounts Payable
153
121
134
112
73
78
84
105
127
151
Accrued Liabilities
36
41
33
44
80
176
159
209
178
162
Short-Term Debt
75
144
172
124
33
30
73
188
128
229
Current Portion of Long-Term Debt
0
0
0
0
0
0
1
0
21
28
Other Current Liabilities
193
171
167
135
179
179
222
300
211
288
Total Current Liabilities
457
476
506
415
365
463
538
801
665
858
Long-Term Debt
0
0
0
5
4
3
0
0
73
522
Deferred Income Tax
0
0
0
1
7
0
0
3
3
2
Minority Interest
140
128
103
77
79
81
78
97
143
123
Other Liabilities
4
11
17
60
107
110
112
116
72
56
Total Liabilities
602
N/A
615
+2%
626
+2%
557
-11%
562
+1%
656
+17%
729
+11%
1 017
+40%
956
-6%
1 561
+63%
Equity
Common Stock
332
332
431
431
431
431
431
431
431
431
Retained Earnings
975
1 120
1 231
1 395
1 629
1 706
1 995
2 299
2 634
2 962
Additional Paid In Capital
118
117
120
109
133
133
128
118
105
101
Other Equity
1
1
3
6
1
1
3
2
1
2
Total Equity
1 426
N/A
1 570
+10%
1 784
+14%
1 940
+9%
2 192
+13%
2 271
+4%
2 557
+13%
2 849
+11%
3 171
+11%
3 496
+10%
Total Liabilities & Equity
2 028
N/A
2 186
+8%
2 410
+10%
2 497
+4%
2 754
+10%
2 927
+6%
3 285
+12%
3 867
+18%
4 127
+7%
5 058
+23%
Shares Outstanding
Common Shares Outstanding
431
431
431
431
431
431
431
431
431
431

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.